Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect

Core Viewpoint - Investors are expected to focus on Viking Therapeutics' pipeline updates during the second-quarter 2025 results announcement on July 23, following a previous earnings miss of approximately 21% [1][6]. Company Overview - Viking Therapeutics currently has no marketed drugs, leading to an expected revenue of zero for the upcoming quarter. The Zacks Consensus Estimate predicts a loss of $0.44 per share [2][7]. Pipeline Developments - The company is advancing three key candidates: VK2735 for obesity, VK2809 for non-alcoholic steatohepatitis (NASH), and VK0214 for X-linked adrenoleukodystrophy (X-ALD) [2][5]. - The phase III VANQUISH program for VK2735 has commenced, focusing on a subcutaneous formulation for adult patients with or without type II diabetes (T2D) over 78 weeks. The program includes two studies: VANQUISH-1 targeting 4,500 participants and VANQUISH-2 targeting 1,100 participants [3][5]. - An oral formulation of VK2735 is being evaluated in a phase II VENTURE-Oral Dosing study, with data expected by the end of the year [4]. Clinical Development Updates - Investors are looking for updates on the dual amylin and calcitonin receptor agonist (DACRA) candidate, with plans to file an investigational new drug (IND) application for obesity by year-end [5]. - Updates on the NASH and X-ALD programs, including collaboration prospects, are also anticipated [5]. Earnings Performance - Viking's earnings history has been mixed, with two earnings beats and two misses over the last four quarters, resulting in a negative average surprise of 1.93%. The company's shares have decreased by 20% year-to-date, contrasting with a 2% decline in the industry [6][7].